The National Institutes of Health announced Saturday that it has halted its trial of the drug hydroxychloroquine for the treatment of adults hospitalized with Covid-19.
"A data and safety monitoring board met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with Covid-19," the NIH said in a statement.
The trial enrolled more than 470 adults patients hospitalized with coronavirus, or in an emergency department with anticipated hospitalization. The study found that those patients who were randomly assigned to receive the hydroxychloroquine treatment didn't benefit from the drug, compared to those in the placebo group.
Hydroxychloroquine is typically used to treat malaria and rheumatoid conditions, such as arthritis.
"In various studies, the drug had demonstrated antiviral activity, an ability to modify the activity of the immune system, and it has an established safety profile at appropriate doses, leading to the hypothesis that it may have also been useful in the treatment of Covid-19," the NIH said in its statement.
On Monday: The US Food and Drug Administration revoked its emergency use authorization for hydroxychloroquine to treat hospitalized patients with coronavirus, saying it was unlikely to provide any benefit based on the latest scientific research.